PARIS - UBS has maintained its neutral stance on the pharmaceutical company Sanofi (EPA:SASY) (NASDAQ:SNY), setting a target price of €100. This valuation reflects the company's confidence in its drug Dupixent and its successors, which were a focal point during their recent investor day.
Sanofi has projected that its new pharmaceutical products, coupled with an expanding vaccine portfolio and the sustained performance of Dupixent, will collectively generate over €10 billion in annual sales by 2030.
The healthcare giant's outlook is buoyed by the potential of its current star treatment, Dupixent, which is anticipated to continue its successful run. The investor day presentations highlighted the drug's capacity to be substituted in the future, which could play a critical role in Sanofi's growth strategy.
Sanofi's ambitious forecast for its pharmaceutical lineup underscores the company's strategic focus on innovation and market expansion. The €10 billion revenue target by 2030 is expected to be driven by a combination of new drug introductions and vaccine developments alongside Dupixent's ongoing success.
Investors and market watchers are keeping a close eye on Sanofi's progress as it aims to achieve these bold financial milestones in the coming years. UBS's current price goal suggests a 16% upside, indicating cautious optimism about the company's ability to meet its targets amidst a competitive pharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.